Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]Macropa-PEG4-IgG
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[225Ac]Macropa-PEG4-IgG is an experimental radiopharmaceutical construct used as a non-targeting isotype control in the development of alpha-particle therapies for Acute Myeloid Leukemia (AML). It consists of the alpha-emitting radioisotope Actinium-225 (225Ac) complexed with the Macropa chelator, which is conjugated to a non-specific immunoglobulin G (IgG) antibody via a PEG4 (polyethylene glycol) linker. The Macropa chelator is specifically optimized for the stable sequestration of large metal ions like 225Ac, while the PEG4 linker helps maintain favorable pharmacokinetics and reduces background tissue binding. In preclinical research, this agent is utilized to establish the baseline effects of non-specific radiation delivery and antibody circulation, allowing researchers to isolate the efficacy of target-specific conjugates like [225Ac]Macropa-PEG4-7065.
- Other names
- [225Ac]Macropa-PEG4-isotype control
02
Targets
CD46 (CD46 Molecule)
Beyond the preview
Go deeper on [225Ac]Macropa-PEG4-IgG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [225Ac]Macropa-PEG4-IgG.